HER2+ Metastatic Breast Cancer (MBC) Active Not Recruiting Phase 3 Trials for Neratinib (DB11828)

IndicationStatusPhase
DBCOND0062591 (HER2+ Metastatic Breast Cancer (MBC))Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs